INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 46h ago
House PTR6h ago
SEC 13F6h ago
Robinhood Chain6h ago

Most active filers · 30d

  1. 01Kurtz George0B / 239S · 10 late239 trades$59.22M
  2. 02SPSaba Capital Management, L.P.68B / 23S · 14 late91 trades$30.01M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  6. 06SJSheena Jonathan0B / 43S43 trades$3.14M
  7. 07CFCheng Chi Fung0B / 42S42 trades$15.33M
  8. 08RJRubinstein Julie0B / 37S37 trades$6.25M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 99 insiders$642K
  4. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  5. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  6. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  7. SELLADUSAddus HomeCare CorpNov 6 – Nov 96 insiders$16.28M
  8. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K

Form 4 transactions

19,215 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
10
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Open-market sale · 10b5-1 plan
SELL$77K
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$35K
25.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$121K
10.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$102K
9,280 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

8
OO
Okupe OluyemiChief Financial Officer
HIMSHims & Hers Health, Inc.
Open-market sale · 10b5-1 plan
SELL$139K
5,262 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

8
GS
Gummadi SuryaPresident - Americas
CTSHCOGNIZANT TECHNOLOGY SOLUTIONS CORP
Open-market sale · 10b5-1 plan
SELL$144K
1,728 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$8,830
200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

6
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$159K
14.7K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

6
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$8,388
720 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

6
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$108K
10.0K sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

5
SC
Saldanha CraigChief Product Officer
YELPYELP INC
Open-market sale · 10b5-1 plan
SELL$33K
1,200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$6,477
2,540 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$20K
1,700 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$30K
2,797 sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

1
BM
Barrett David MichaelDirector, Chief Executive Officer
EXFYExpensify, Inc.
Open-market sale · 10b5-1 plan
SELL$44K
30.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$1,398
556 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

1
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$75K
381 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
SN
Sieffert Kristen NPresident
FOAFinance of America Companies Inc.
Open-market sale · 10b5-1 plan
SELL$17K
750 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$4,535
23 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$4,499
23 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$7,449
39 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$192
1 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

37
RJ
Running Michael J.Regional President - AMER
PLXSPLEXUS CORP
Open-market sale
SELL$190K
926 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

33
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale
SELL$165K
1,662 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

33
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale
SELL$117K
1,166 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

30
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale
SELL$49K
492 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

29
LE
Lee David EricVICE CHAIR, WINTRUST FINANCIAL
WTFCWINTRUST FINANCIAL CORP
Open-market sale
SELL$82K
558 sh
Jan 30, 2026Feb 3, 2026
traded Jan 30, 2026
+4dSEC Form 4

Evidence

26
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale
SELL$8,999
93 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

19
RL
Robinson Jill L.EVP, CFO & Treasurer
BATRKAtlanta Braves Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$800K
20.0K sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

10
MJ
Malcolm JanDirector
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$24K
50 sh
Feb 3, 2026Feb 3, 2026
traded Feb 3, 2026
+0dSEC Form 4

Evidence

10
SM
Smith Chad M.Pres & COO, Better Mortgage
BETRBetter Home & Finance Holding Co
Open-market sale · 10b5-1 plan
SELL$84K
3,097 sh
Feb 3, 2026Feb 3, 2026
traded Feb 3, 2026
+0dSEC Form 4

Evidence

9
OC
Ohlgart ChristianeChief Financial Officer
FTNTFortinet, Inc.
Open-market sale · 10b5-1 plan
SELL$41K
507 sh
Feb 3, 2026Feb 3, 2026
traded Feb 3, 2026
+0dSEC Form 4

Evidence

6
JD
Jedrzejek DavidSVP and General Counsel
LEVILEVI STRAUSS & CO
Open-market sale · 10b5-1 plan
SELL$44K
2,248 sh
Feb 3, 2026Feb 3, 2026
traded Feb 3, 2026
+0dSEC Form 4

Evidence

4
BP
Badjate PramodPresident & GM, NFB
NTGRNETGEAR, INC.
Open-market sale · 10b5-1 plan
SELL$63K
3,000 sh
Feb 2, 2026Feb 3, 2026
traded Feb 2, 2026
+1dSEC Form 4

Evidence

1
SE
Schubach Sarah ElizabethChief Accounting Officer
DBXDROPBOX, INC.
Open-market sale · 10b5-1 plan
SELL$38K
1,462 sh
Jan 30, 2026Feb 3, 2026
traded Jan 30, 2026
+4dSEC Form 4

Evidence

39
DJ
Donovan James JosephChief Lending Officer/FSVP
UNTYUNITY BANCORP INC /NJ/
Open-market sale
SELL$14K
265 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC Form 4

Evidence

35
KE
Krohne Susan EChief Legal Officer, Secretary
MHOM/I HOMES, INC.
Open-market sale
SELL$671K
5,000 sh
Jan 30, 2026Feb 2, 2026
traded Jan 30, 2026
+3dSEC Form 4

Evidence

22
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$154K
3,500 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC Form 4

Evidence

22
DA
Dandekar AtulCSBO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$126K
2,800 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC Form 4

Evidence

21
Thomas RagyDirector
CXMSprinklr, Inc.
Open-market sale
SELL$6,693
1,054 sh
Jan 29, 2026Feb 2, 2026
traded Jan 29, 2026
+4dSEC Form 4

Evidence

Page 348 of 481
← PrevNext →